Ten drugs filed with regulators have potential to become billion-sellers by 2025 according to new research, with a near-copy of Roche’s rituximab from Amgen and Allergan showing the most potential.

A Dutch man with lymphoma and other blood disorders was infected with the COVID-causing virus for nearly two years, during ...

Although histological transformation to diffuse large B-cell lymphoma (DLBCL) remains a common complication of follicular ...

A recent trial aimed to explore whether B cell–depleting therapy with rituximab, an anti-CD20 monoclonal antibody, would prove effective in PPMS (Hawker et al, 2009). The authors performed a ...

Rituximab, a chimeric monoclonal anti-CD20 IgG1 antibody, induces complement-dependent and antibody-dependent destruction of all B-lineage cells, except plasma and pre-B cells, which do not ...

Two studies have reported promising results on the use of rituximab for the treatment of graft rejection in pediatric and young adult renal transplant recipients. Billing et al.'s pilot study ...

As AbbVie and Johnson & Johnson’s Imbruvica retreated, AstraZeneca’s Calquence has become the first BTK inhibitor to claim a ...

B cell deficiency is a common condition that can result either from immunosuppressant drugs used to treat autoimmune disease or certain cancers -; such as rituximab (RTX) -; or from natural immune ...

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

IQVIA, in its broad 2023 assessment of biosimilar savings — which did break out OOP costs — optimistically projectd between ...

Out of the 40 analysts that have coverage on Dr. Reddy's, 14 of them have a "sell" rating, while 15 of them have a "buy" call ...

Q1 2024 Earnings Call Transcript May 6, 2024 ADC Therapeutics SA reports earnings inline with expectations. Reported EPS is $-0.56 EPS, expectations were $-0.56. ADCT isn’t one of the 30 most popular ...